Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Robert Weinstein

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Endo
Address8/813 Cancer Institute
4104 Outpatient Circle
Mail Slot # 587
Little Rock AR 72205
Phone501-686-5130
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Robert S. Weinstein, M.D. is a professor of medicine in the Division of Endocrinology and Metabolism. He received his medical degree from the University of Illinois Medical Center in Chicago. He completed a post-doctoral fellowship in Endocrinology from the University of Miami School of Medicine.Dr. Weinstein is a Diplomat with the American Board of Internal Medicine, with specialties in Internal Medicine and Endocrinology and Metabolism. He is also a member of the American Association for the Advancement of Science, the American Society for Bone and Mineral Research, the Endocrine Society and the Arkansas Medical Society.


    Collapse Research 
    Collapse research activities and funding
    R01AR049794     (OBRIEN, CHARLES A)Apr 1, 2022 - Mar 31, 2027
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Osteocyte Control of Bone Remodeling
    Role: Co-Investigator
    I01BX000436     (WEINSTEIN, ROBERT STEWART)Apr 1, 2009 - Jun 30, 2018
    NIH
    Glucocorticoid-induced osteonecrosis of the hip, osteocytes and canalicular fluid
    Role: Principal Investigator
    200515502     (WEINSTEIN, ROBERT S)Jan 1, 2006 - Dec 31, 2008
    Amgen, Inc.
    Interference with RANKL Prevents Increased Cancellous Osteoclast Number and Lifespan in Mice Receiving Excess Glucocorticoids
    Role: Principal Investigator
    animal rearch     (WEINSTEIN, ROBERT S)Feb 1, 2003 - Dec 30, 2006
    Procter & Gamble
    Bisphosphonate effects on osteoclasts and osteocytes in glucocorticoid-induced osteoporosis: relationship to fracture prevention.
    Role: Principal Investigator
    animalrearch     (WEINSTEIN, ROBERT)Feb 1, 2003 - Dec 30, 2006
    Procter & Gamble
    Bisphosphonate effects on osteoclasts and osteocytes in glucocorticoid-induced osteoporosis: relationship to fracture prevention.
    Role: Principal Investigator
    in vitro     (WEINSTEIN, ROBERT S)Feb 1, 2003 - Jan 31, 2004
    Procter & Gamble
    Bisphosphonate effects on osteoclasts and osteocytes in vitro: mechanisms of inhibition of glucocorticoid-induced apoptosis of osteocytes
    Role: Principal Investigator
    invitro     (WEINSTEIN, ROBERT)Feb 1, 2003 - Jan 31, 2004
    Procter & Gamble
    Bisphosphonate effects on osteoclasts and osteocytes in vitro: mechanisms of inhibition of glucocorticoid-induced apoptosis of osteocytes
    Role: Principal Investigator
    CZOL446H2301/CENTER # 0564     (WEINSTEIN, ROBERT)Jan 11, 2002 - Aug 1, 2006
    NOVARTIS Pharmaceuticals Corporation
    A Multi-Center, Double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of Zoledronic acid in the treatment of osteopor
    Role: Principal Investigator
    CZOL446H2301/CENTER#0564     (WEINSTEIN, ROBERT S)Jan 11, 2002 - Aug 1, 2006
    NOVARTIS Pharmaceuticals Corporation
    A Multi-Center, Double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of Zoledronic acid in the treatment of osteopor
    Role: Principal Investigator
    R01AR046191     (WEINSTEIN, ROBERT STEWART)Sep 15, 1999 - Aug 31, 2006
    NIH
    The Role of Osteocyte Survival in Bone Strength
    Role: Principal Investigator
    P01AG013918     (MANOLAGAS, STAVROS C.)Aug 27, 1996 - Apr 30, 2018
    NIH
    Molecular and Cellular Mechanisms of Osteoporosis
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Zhu M, Zeiss C, Hamrick MW, Weinstein RS, Sun BH, Brotto M, Liu X, Siu E, Huttner A, Tommasini S, Simpson C, Insogna K. Mitofusin 2 plays a critical role in maintaining the functional integrity of the neuromuscular-skeletal axis. Bone. 2024 Mar 27; 117086. PMID: 38552893.
      View in: PubMed
    2. Whyte MP, Aronson J, McAlister WH, Weinstein RS, Wenkert D, Clements KL, Gottesman GS, Madson KL, Stolina M, Bijanki VN, Plotkin H, Huskey M, Duan S, Mumm S. Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V. Bone. 2021 04; 145:115835. PMID: 33360005.
      View in: PubMed
    3. Menon LP, Weinstein RS. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron. Bone. 2020 02; 131:115137. PMID: 31756522.
      View in: PubMed
    4. Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 06 06; 9(1):2193. PMID: 29875355.
      View in: PubMed
    5. Weinstein RS, Hogan EA, Borrelli MJ, Liachenko S, O'Brien CA, Manolagas SC. The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice. Endocrinology. 2017 11 01; 158(11):3817-3831. PMID: 28938402.
      View in: PubMed
    6. Piemontese M, Almeida M, Robling AG, Kim HN, Xiong J, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA, Jilka RL. Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight. 2017 09 07; 2(17). PMID: 28878136.
      View in: PubMed
    7. Fabbro MD, Taschieri S, Canciani E, Addis A, Musto F, Weinstein R, Dellavia C. Osseointegration of Titanium Implants With Different Rough Surfaces: A Histologic and Histomorphometric Study in an Adult Minipig Model. Implant Dent. 2017 Jun; 26(3):357-366. PMID: 28234707.
      View in: PubMed
    8. Taschieri S, Corbella S, Weinstein R, Di Giancamillo A, Mortellaro C, Del Fabbro M. Maxillary Sinus Floor Elevation Using Platelet-Rich Plasma Combined With Either Biphasic Calcium Phosphate or Deproteinized Bovine Bone. J Craniofac Surg. 2016 May; 27(3):702-7. PMID: 27046471.
      View in: PubMed
    9. Liu Y, Almeida M, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Skeletal inflammation and attenuation of Wnt signaling, Wnt ligand expression, and bone formation in atherosclerotic ApoE-null mice. Am J Physiol Endocrinol Metab. 2016 May 01; 310(9):E762-73. PMID: 26956187.
      View in: PubMed
    10. Zhu M, Sun BH, Saar K, Simpson C, Troiano N, Dallas SL, Tiede-Lewis LM, Nevius E, Pereira JP, Weinstein RS, Tommasini SM, Insogna KL. Deletion of Rac in Mature Osteoclasts Causes Osteopetrosis, an Age-Dependent Change in Osteoclast Number, and a Reduced Number of Osteoblasts In Vivo. J Bone Miner Res. 2016 Apr; 31(4):864-73. PMID: 26496249.
      View in: PubMed
    11. Ucer S, Iyer S, Bartell SM, Martin-Millan M, Han L, Kim HN, Weinstein RS, Jilka RL, O'Brien CA, Almeida M, Manolagas SC. The Effects of Androgens on Murine Cortical Bone Do Not Require AR or ERa Signaling in Osteoblasts and Osteoclasts. J Bone Miner Res. 2015 Jul; 30(7):1138-49. PMID: 25704845.
      View in: PubMed
    12. Piemontese M, Onal M, Xiong J, Wang Y, Almeida M, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA. Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone. 2015 Jun; 75:18-26. PMID: 25700544.
      View in: PubMed
    13. Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA. Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone. 2014 Sep; 66:146-54. PMID: 24933342.
      View in: PubMed
    14. Bartell SM, Kim HN, Ambrogini E, Han L, Iyer S, Serra Ucer S, Rabinovitch P, Jilka RL, Weinstein RS, Zhao H, O'Brien CA, Manolagas SC, Almeida M. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014 Apr 30; 5:3773. PMID: 24781012.
      View in: PubMed
    15. Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res. 2014 Jan; 29(1):103-17. PMID: 23761243.
      View in: PubMed
    16. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014 Jan; 29(1):1-23. PMID: 23712442.
      View in: PubMed
    17. Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, de Cabo R, Jilka RL, Weinstein RS, O'Brien CA, Manolagas SC, Almeida M. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest. 2013 Aug; 123(8):3409-19. PMID: 23867625.
      View in: PubMed
    18. Onal M, Piemontese M, Xiong J, Wang Y, Han L, Ye S, Komatsu M, Selig M, Weinstein RS, Zhao H, Jilka RL, Almeida M, Manolagas SC, O'Brien CA. Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem. 2013 Jun 14; 288(24):17432-40. PMID: 23645674.
      View in: PubMed
    19. Capelli M, Testori T, Galli F, Zuffetti F, Motroni A, Weinstein R, Del Fabbro M. Implant-buccal plate distance as diagnostic parameter: a prospective cohort study on implant placement in fresh extraction sockets. J Periodontol. 2013 Dec; 84(12):1768-74. PMID: 23472878.
      View in: PubMed
    20. Bartell SM, Han L, Kim HN, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Chambliss KL, Shaul PW, Roberson PK, Weinstein RS, Jilka RL, Almeida M, Manolagas SC. Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. Mol Endocrinol. 2013 Apr; 27(4):649-56. PMID: 23443267.
      View in: PubMed
    21. Weinstein RS. The ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Glucocorticoid-Induced Osteoporosis. 2013.
    22. Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates bone porosity with age. J Bone Mineral Res. 2013.
    23. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013; 123(1):394 - 404.
    24. Jilka RL, Noble B, Weinstein RS. Osteocyte apoptosis. Bone. 2013 Jun; 54(2):264-71. PMID: 23238124.
      View in: PubMed
    25. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Estrogen receptor-a signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013 Jan; 123(1):394-404. PMID: 23221342.
      View in: PubMed
    26. Srividhya Iyer, Elena Ambrogini, Li Han, Shoshana Bartell, Aaron Warren, Julie Crawford, Paula Roberson, Robert Weinstein, Charles O'Brien, Maria Jose Almeida, Stavros Manolagas. Deletion of FoxO1, 3, and 4 from Osteoprogenitor Cells Increases Bone Mass throughout Life and Attenuates Adiposity in Aged Bone. Journal of Bone and Mineral Research. 2012; S23.
    27. Shoshana Bartell, Aaron Warren, Li Han, Srividhya Iyer, Sung Kim, Benita Katzenellenbogen, Ken Chambliss, Philip Shaul, John Katzenellenbogen, Paula Roberson, Robert Weinstein, Charles O'Brien, Robert Jilka, Maria Jose Almeida, Stavros Manolagas. An Estrogen Dendrimer Conjugate Incapable of Stimulating the Nuclear-initiated Actions of Estrogen Receptors Prevents the Loss of Cortical Bone Mass in Estrogen Deficient Mice. Journal of Bone and Mineral Research. 2012; S21.
    28. Melda Onal, Jinhu Xiong, Shiqiao Ye, Li Han, Robert Jilka, Robert Weinstein, Maria Jose Almeida, Haibo Zhao, Stavros Manolagas, Charles O'Brien. Suppression of Autophagy in Osteoblasts and Osteocytes Increases Oxidative Stress and Recapitulates the Effects of Aging on the Murine Skeleton. Journal of Bone and Mineral Research. 2012; S349.
    29. Robert Weinstein, Erin Hogan, Charles O'Brien, Stavros Manolagas. Glucocorticoids Act Directly on Osteocytes to Reduce Bone Vascularity and Strength. Journal of Bone and Mineral Research. 2012; S469.
    30. Robert Jilka, Annick DeLoose, Leslie Climer, Lynda Bonewald, Robert Weinstein, Charles O'Brien, Stavros Manolagas. Dysfunctional Osteocytes Increase RANKL and Promote Cortical Pore Formation in Their Vicinity: a Mechanical Explanation for the Development of Cortical Porosity with Age. Journal of Bone and Mineral Research. 2012; S348.
    31. Srividhya Iyer, Aaron Warren, Martha Martin-Millan, Li Han, Shoshana Bartell, Elena Ambrogini, Jinhu Xiong, Julie Crawford, Robert Weinstein, Robert Jilka, Charles O'Brien, Maria Jose Almeida, Stavros Manolagas. The ERa of Osteoblast Progenitors is Required for Normal Accrual of Cortical Bone Mass Independently of Estrogens. Journal of Bone and Mineral Research. 2012; S68.
    32. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012 Sep; 41(3):595-611. PMID: 22877431.
      View in: PubMed
    33. Onal M, Galli C, Fu Q, Xiong J, Weinstein RS, Manolagas SC, O'Brien CA. The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol. 2012 Feb; 26(2):341-8. PMID: 22207718.
      View in: PubMed
    34. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012 Apr; 41(2):183-90. PMID: 22169965.
      View in: PubMed
    35. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011; 286(52):44326 - 44335.
    36. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor a increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011 Dec 30; 286(52):44326-35. PMID: 22030390.
      View in: PubMed
    37. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011 Sep 11; 17(10):1235-41. PMID: 21909103.
      View in: PubMed
    38. Weinstein RS, O'Brien CA, Almeida M, Zhao H, Roberson PK, Jilka RL, Manolagas SC. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology. 2011 Sep; 152(9):3323-31. PMID: 21771887.
      View in: PubMed
    39. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011 Jul 07; 365(1):62-70. PMID: 21732837.
      View in: PubMed
    40. Weinstein RS. Cecil Textbook of Medicine. Osteomalacia and Rickets. 2011; 252.
    41. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 Nov; 25(11):2267-94. PMID: 20842676.
      View in: PubMed
    42. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010 Nov; 25(11):2427-37. PMID: 20533302.
      View in: PubMed
    43. Jilka RL, Almeida M, Ambrogini E, Han L, Roberson PK, Weinstein RS, Manolagas SC. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell. 2010 Oct; 9(5):851-67. PMID: 20698835.
      View in: PubMed
    44. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5?mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010 Oct; 25(10):2239-50. PMID: 20499357.
      View in: PubMed
    45. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology. 2010 Jun; 151(6):2641-9. PMID: 20410195.
      View in: PubMed
    46. Almeida M, Martin-Millan M, Ambrogini E, Bradsher R, Han L, Chen XD, Roberson PK, Weinstein RS, O'Brien CA, Jilka RL, Manolagas SC. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res. 2010 Apr; 25(4):769-81. PMID: 19821774.
      View in: PubMed
    47. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010 Feb 03; 11(2):136-46. PMID: 20142101.
      View in: PubMed
    48. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010 Feb; 24(2):323-34. PMID: 20053716.
      View in: PubMed
    49. Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, Roberson PK, Boskey AL, Clemens TL, Manolagas SC. Endogenous Glucocorticoids Decrease Vascularity and Increase skeletal Fragility in Aged Mice. Aging Cell. 2010; (9):147-67.
    50. Weinstein RS, O'Brien CA, Zhao, H, Roberson PK, Manolagas SC. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis, decreased bone interstitial fluid, and reduced strenght in mice( in preparation. 2010.
    51. Weinstein RS, Orwoll ES, Miller PD, Adachi JD, Brown J, Adler R, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P. Efficacy and safety of a once-yeearly i.v. infusion of zoledronic acid 5mg versus a once weekly 70 mg oral alendronate in the treatment of male osteoporpsis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010.
    52. Weinstein RS, Ambrogini E, Almeida M, Martin-Millan M, Paik J-H, DePinho RA, Han L, Goellner J, Jilka RL, O'Brien CA, Manolagas SC. Fox-O-mediated defense against oxidative stress in osteoblasts is indispensable for skelatal homostasis in mice. 2010; (11):136-46.
    53. Weinstein RS. Review-Glucocorticoids, Osteocytes and Skeletal fragilty: The Role of Bone Vascularity. 2010; (46):564-570.
    54. Weinstein R, Almeida M, Martin-Millam M, Ambrogini E, Bradsher III R, Han L, Chen X-D, Roberson PK, O'Brien CA, Jilka, RL, Manolagas SC. Estrogens attenuate oxidative stress and osteoblast differentiation, proliferation and apoptosis by DNA binding-independent actions of the ERa. J Bone Mineral Res. 2010; 25:769-781.
    55. Weinstein RS, Martin-Millan M, Almeida M, Ambrogini E, Han L, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor a in osteoclasts mediates the protective effects of estrogen on cancellous but not cortical bone. Molecular Endocrinol. 2010; 24:323-4.
    56. Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, Thostenson J, Roberson PK, Boskey AL, Clemens TL, Manolagas SC. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010 Apr; 9(2):147-61. PMID: 20047574.
      View in: PubMed
    57. Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone. 2010 Mar; 46(3):564-70. PMID: 19591965.
      View in: PubMed
    58. Jain N, Weinstein RS. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol. 2009 Jun; 5(6):341-6. PMID: 19491914.
      View in: PubMed
    59. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009 Jan 01; 360(1):53-62. PMID: 19118304.
      View in: PubMed
    60. Weinstein RS. In: ES Orwoll (ed) Atlas of Osteoporosis. Understanding Bone Histomorphometry: Sampling, Evaluation, and Interpretation. 2009; 2.
    61. Jain N, Weinstein RS. Giant Osteoclast Formation After Long-Term Oral Bisphosphonate Therapy. Nat Rev Rheumatol. 2009; 5(6):341-6.
    62. Weinstein RS, Jilka RL, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration prevents glucocorticoid-induced osteoblast and osteocyte apoptosis, decreased bone formation, and reduced bone strength in mice. Endocrinol doi. 2009; (10.1210):1488.
    63. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008 Nov; 23(11):1712-21. PMID: 18597631.
      View in: PubMed
    64. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009 Feb; 44(2):275-86. PMID: 19010455.
      View in: PubMed
    65. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008 Aug 13; 3(8):e2942. PMID: 18698360.
      View in: PubMed
    66. Jilka RL, Bellido T, Almeida M, Plotkin LI, O'Brien CA, Weinstein RS, Manolagas SC. In: Principles of Bone Biology. John Bilezikian, Lawrence Raisz, T. John Martin, eds. Apoptosis of Bone Cells. 2008; 13.
    67. Weinstein RS. In: C Rosen (ed) The ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. The cover photomicrograph and Chapter on Glucocorticoid-Induced Osteoporosis. 2008.
    68. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology. 2008 Jan; 149(1):146-53. PMID: 17932217.
      View in: PubMed
    69. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007 Oct; 22(10):1492-501. PMID: 17542686.
      View in: PubMed
    70. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007 Sep 14; 282(37):27285-27297. PMID: 17623659.
      View in: PubMed
    71. Taschieri S, Del Fabbro M, Testori T, Weinstein R. Efficacy of xenogeneic bone grafting with guided tissue regeneration in the management of bone defects after surgical endodontics. J Oral Maxillofac Surg. 2007 Jun; 65(6):1121-7. PMID: 17517295.
      View in: PubMed
    72. Weinstein RS. Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures? Nat Clin Pract Endocrinol Metab. 2007 Feb; 3(2):86-7. PMID: 17237833.
      View in: PubMed
    73. Weinstein RS, Chambers TM, Wicker CA, Webb WW, Hogan EA, Manolagas SC. Giant Osteoclast Formation After Long-Term Oral Aminobisphosphonate Therapy for Postmenopausal Osteoporosis. J Bone Miner Res 22(suppl 1): S17. 2007.
    74. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA. Targeted deletion of a distant transcriptional enhancer of the RANKL gene reduces bone remodeling and increases bone mass. Endocrinology 149:146-153. 2007.
    75. Weinstein RS, Goellner J, Chambers TM, Hogan EA, Berryhill SB, Shelton RS, Manolagas SC. Glucocorticoids, Aging and Bone Hydration: New Insights into Qualitative Aspects of Bone Strength. J Bone Miner Res 22(suppl 1): S25. 2007.
    76. Szumska D, Benes H, Kang P, Weinstein RS, Jilka RL, Manolagas SC, Shmookler Reis RJ. A novel locus on the X chromosome regulates post-maturity bone density changes in mice. Bone. 2007 Mar; 40(3):758-66. PMID: 17185055.
      View in: PubMed
    77. Manolagas SC, Jilka RL, Kousteni S, Bellido T, Weinstein RS, O'Brien CA, Plotkin L, Han L. Response to Windahl et al. J Clin Invest. 2006 Nov; 116(11):2834. PMID: 17080186.
      View in: PubMed
    78. Aguirre JI, Plotkin LI, Stewart SA, Weinstein RS, Parfitt AM, Manolagas SC, Bellido T. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res. 2006 Apr; 21(4):605-15. PMID: 16598381.
      View in: PubMed
    79. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther. 2006; 8(5):219. PMID: 17049069.
      View in: PubMed
    80. Weinstein RS, Jia D, Chambers TM, Hogan EA, Berryhill SB, Shelton RS, Stewart SA, Jilka RL, Manolagas SC. Aging C57BL/6 Mice Exhibit Increased Glucocorticoid Production in Association with Decreased Bone Formation. Wall Width and Canalicular Circulation: Novel Mechanistic Insights into the Involutional Loss of Bone Mass and Strength. J Bone Miner Res 21(suppl 1): S62. 2006.
    81. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab. 2005 Nov; 289(5):E784-93. PMID: 15956054.
      View in: PubMed
    82. Weinstein RS. IIB-HSD: Guardian or Gate Crasher?. BoneKEy-Osteo Vision 2: p. 6-13 http://www.bonekey-ibms.org/cgi/content/full/ibmske;2/9/6?ct. 2005.
    83. Weinstein RS, Goellner JJ, Jia D, Shelton RS, Parfitt AM, Manolagas SC. Glucocorticoid Excess Disrupts the Canalicular Circulation: Potential Mechanism of the Disparity Between Bone Density and Strength in Glucocorticoid-Induced Osteoporosis and Osteonecrosis. J Bone Miner Res 20(suppl 1): S50. 2005.
    84. Weinstein RS, Manolagas SC. Apoptosis in glucocorticoid-induced bone disease. Curr Opin Endocrinol Diabetes 12:219-223. 2005.
    85. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005 Mar; 146(3):1226-35. PMID: 15591153.
      View in: PubMed
    86. Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology. 2004 Apr; 145(4):1980-7. PMID: 14715712.
      View in: PubMed
    87. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Deflection of Glucocorticoid Action on Osteoclasts from TRAP-11B-HSD2 Transgenic Mice Abrogates the Antiapoptotic Effects of the Steroid. J Bone Miner Res 19(suppl 1): S303. 2004.
    88. Weinstein RS, Jia D, O'Brien CA, Stewart SA, Manolagas SC. Transient Stimulation of RANKL and Persistent Inhibition of Osteoprotegerin Expression by Glucocorticoid Administration in Mice: Molecular Correlates of Glucocorticoid Effects on Vertebral Osteoclast Numbers. J Bone Miner Res 19(suppl 1): S435. 2004.
    89. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004 Apr; 145(4):1835-41. PMID: 14691012.
      View in: PubMed
    90. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003 Dec 12; 278(50):50259-72. PMID: 14523023.
      View in: PubMed
    91. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int. 2003 Oct; 14(10):814-22. PMID: 14610642.
      View in: PubMed
    92. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003 Feb; 52(2):268-76. PMID: 12540596.
      View in: PubMed
    93. Weinstein RS, Jia D, O'Brien CA, Powers CC, Crawford JA, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC. Suppression of osteoblastogenesis overrides the purported effects of hypogonadism in glucocorticoid-induced osteoporosis. J Bone Miner Res 18(supple 2): S367. 2003.
    94. Weinstein RS. Human Bone Biopsy. 2003; 6.
    95. Weinstein RS, Powers CC, Parfitt AM, Manolagas SC. Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strength. J Bone Miner Res 17(supple 1): S156. 2002.
    96. Nair G, Weinstein RS. Glucocorticoid Excess Radiology Quiz. Resident & Staff Physician 48:61 and 65. 2002.
    97. Weinstein RS, O'Brien CA, Crawford JA, Manolagas SC. Osteoblast Specific Expression of 11B-HSD2 in Transgenic Mice Abrogates Steroid-Induced Apoptosis and Attenuates Loss of BMD and Strength. J Bone Miner Res 17(supple 1): S131. 2002.
    98. Weinstein RS, Meunier PJ, Geusens P, Bone H, Tonino RP, Ross PD, Santora A. Skeletal benefits are maintained through 7 years of alendronate treatment. J Bone Miner Res 16(supple 1):S529. 2001.
    99. O'Brien CA, Weinstein RS, Powers C, Manolagas SC. Increased RANKL Expression and Osteoclast Numbers, but No Change in Osteoblast Number or Apoptosis in a Murine Model of Sustained PTH Elevation: Mechanism of Decreased Bone Density and Strength. J Bone Miner Res 16(supple 1):S303. 2001.
    100. Shmookler Reis RJ, Benes H, McClure T, Kang P, Weinstein RS, Shelton RS, Jilka RL, Manolagas SC. The effect of sex on genetic determinates of Pre- and Post-maturity bone accrual in mice. J Bone Miner Res 16(supple 1):S351, 2001. 2001.
    101. Ali AA, O'Brien CA, Weinstein RS, Roberson P, Manolagas SC, Jilka RJ. An Inverse Relationship between Prevalence of Osteoblast Apoptosis and Rate of Bone Formation with Intermittent, but not Sustained, Elevation of PTH in Mice. J Bone Miner Res 16(supple 1): S178. 2001.
    102. Weinstein RS, Powers C, Landes R, Parfitt AM, Manolagas SC. Prednisolone Administration Ameliorates the Increased Osteoclastogenesis But Aggravates the Loss of Osteocytes and Bone Strength That Follow Orchidectomy. J Bone Miner Res 16(supple 1):S280. 2001.
    103. Jilka RL, Lecka-Czernik B, Ali AA, O'Brien CE, Weinstein RS, Manolagas SC. Activation of PPARy2 by Rosiglitazone Causes Bone Loss Associated with Increased Marrow Adiposity and Decreased Osteoblast Number in Mice. J Bone Miner Res 16(supple 1):S319. 2001.
    104. Boyce BF, Xing L, Jilka RL, Bellido T, Weinstein RS, Parfitt AM, Manolagas SC. Apoptosis in Bone Cells. 2001; 151-168.
    105. Weinstein RS. The pathogenesis of glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 18 (Suppl. 21):S35-40. 2000.
    106. Borton AJ, Frederick JP, Datto MP, Wang X, Weinstein RS. An Essential Role for Smad3 in Bone Formation through Regulation of Osteoblast Differentiation. J Bone Miner Res 15 (supple 1):S189. 2000.
    107. Weinstein RS. Perspective: True Strength. J Bone Miner Res 15:621-625. 2000.
    108. Shmookler Reis RJ, Benes H, McClure T, Weinstein RS, Shelton RS, Jilka RL, Manolagas SC. Distinct Loci Determine Pre- and Post-Maturity Bone Accrual in Mice. J Bone Miner Res 15 (supple 1):S260. 2000.
    109. Weinstein RS, Crawford JA, Swain FL, Manolagas SC, Parfitt AM. Early Bisphosphonate Treatment Prevents the Long Term Adverse Effects of Glucocorticoid-Induced Osteoporosis in Mice. J Bone Miner Res 15 (supple 1):S172. 2000.
    110. O'Brien CA, Swain FL, Crawford JA, Plotkin LI, Manolagas SC, Weinstein RS. 11B-Hydroxysteriod Dehydrogenase Type 2 (11B-HSD2) Overexpression Prevents Glucocorticoid-Induced Apoptosis of Osteoblastic Cells: A Novel Strategy for Dissecting the Mechanism of Steroid-Induced Osteoporosis. J Bone Miner Res 15 (supple 1):S167. 2000.
    111. Manolagas SC, Weinstein RS, Jilka RL. Basic Principles of Bone Physiology. 1999; 1.
    112. Weinstein RS, T Bellido, TM Chambers, JA Crawford, FL Swain, L Han, SC Manolagas. Like Estrogen, Androgen Exert Potent and Direct Anti-apoptotic Effects on Osteoblasts and Osteocytes in vivo and in vitro. J Bone Miner Res 14:S451. 1999.
    113. Weinstein RS, TM Chambers, JA Crawford, FL Swain, AM Parfitt, RL Jilka, SC Manolagas. A Strong Positive Correlation Between the Prevalence of Osteoblast Apoptosis and the Activation Frequency Across a Wide Range of Bone Remodeling Rates. J Bone Miner Res 14:S342. 1999.
    114. Weinstein RS, Nicholas RW, Kirchner JR, Crawford JA, Skinner RA, Swain FL, Manolagas SC. Anatomic juxtaposition of apoptotic osteocytes and avascular necrosis in femurs from patients with glucocorticoid excess. Bone 23:S461. 1998.
    115. Jilka RL, Weinstein RS, Roberson P, Shelton R, Swain F, Smith C, Kirchner J, Parfitt AM, Manolagas SC. PTH increases bone formation by postponing osteoblast apoptosis, not by increasing precursor proliferation. Bone 23:S519. 1998.
    116. Manolagas SC, Weinstein RS. Editorial: Glucocorticoid-induced osteoporosis; new developments in pathogenesis and treatment. Harrison's Principles of Internal Medicine (Harrison's Online) McGraw-Hill. 1998.
    117. Weinstein RS, Jilka RL, Young C, Miller FL, Shelton R, Smith C, Parfitt AM, Manolagas SC. Glucocorticoid excess decreases the number of osteoblast progenitors in the marrow and increases osteoblast apoptosis. J Bone Min Res 12:S165. 1997.
    118. Weinstein RS, Jilka RL, Miller FL, Parfitt AM, Manolagas SC. Glucocorticoid excess causes apoptosis of osteocytes in murine cortical bone. J Bone Min Res 12:S142. 1997.
    119. Benes H, Dennis R, Zheng W, Weinstein RS, Shelton R, Jilka RL, Roberson P, Manolagas SC, Reis RJS. Genetic mapping of osteopenia-associated loci using crosses between closely related mouse strains with differing bone density. J Bone Min Res 12:S375. 1997.
    120. Weinstein RS, Miller FL, Shelton R, Smith C, Roberson P, Parfitt AM, Manolagas SC, Jilka RL. The effects of androgen deficiency on bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. J Bone Min Res 11:S129. 1996.
    121. Parfitt AM, Jilka RL, Weinstein RS, Bellido T, Manolagas SC. The spacial and temporal relationships between osteoclasts and osteoblasts during bone remodeling require parallel as well as serial signal pathways. J Bone Min Res 11:S382. 1996.
    122. Jilka RL, Weinstein RS, Bellido T, Miller FL, Smith C, Parfitt AM, Manolagas SC. Demonstration of programmed cell death (apoptosis) in osteoblasts: evidence for modulation of this process by growth factors and cytokines. J Bone Min Res 11:S144. 1996.
    123. Benes H, Takahaski K, Zheng W, Weinstein RS, Shelton R, Jilka RL, Manolagas SC, Reis RJS. Polymorphic microsatellite markers distinguish three AKR mouse substrains that exhibit different levels of bone mineral density. J Bone Min Res 11:S331. 1996.
    124. Reis RJS, Weinstein RS, Jilka RL, Manolagas SC. A Strategy for Chromosome Mapping of Osteoporosis-Associated Genes in the Senescence Accelerated Mouse (SAM): Use of High-Resolution Dual-Energy X-Ray Absorptiometry. J Bone Min Res 10:S161. 1995.
    125. Halstead LR, Weinstein RS, Cheng SL, Rifas L, Avioli LV. Effects of 22-oxacalcitriol on mineral and skeletal metabolism in young X-linked hypophosphatemic male mice: comparison with calcitriol. J Bone Min Res 10:S390. 1995.
    126. Siris E, Reid I, Weinstein RS, Yates AJ, Lombardi A, Musliner T, Thompson D, Daifotis A, Hirsch L. Alendronate is an effective treatment for Paget's disease regardless of patient characteristics. J Bone Min Res 10:S299. 1995.
    127. Weinstein RS, Butch AW, Reep PJ, Pappas A, Ferris E, Lindsey DC, White PL, Parfitt AM, Jagannath S, Manolagas SC, Barlogie B. Evidence of Systemic Bone Disease in a Cohort of 220 Patients with Multiple Myeloma: Loss of Cancellous Bone and Increased Radial Cortical Bone Independent of Focal Lytic Lesions. J Bone Min Res 10:S195. 1995.
    128. Weinstein RS, Takahashi K, Miller FL, White PL, Lindsey DC, Parfitt AM, Manolagas SC, Jilka RL. Chronological Linkage Between Impaired Osteoblastogenesis in the Bone Marrow, Decreased Bone Formation Rate and Low Bone Mineral Density in the Senescence Accelerated Mouse. J Bone Min Res 10:S444. 1995.
    129. Weinstein RS, Bone H, Tucci J, Downs R, Harris S, Licata A, Genant H, Recker R. Polvino: Alendronate Treatment of Osteoporosis in Elderly Women. J Bone Min Res 9:S144. 1994.
    130. Weinstein RS, McKie MS. The Rate of Bone Resorption in Paget's Disease. J Bone Min Res 9:S429. 1994.
    131. Gies AA, Majumdar S, Weinstein RS, Mote CD. Digital Stereology and Fourier Analysis for Evaluation of Cancellous Bone. J Bone Min Res 8:S313. 1993.
    132. Weinstein RS, Majumdar S. Fractal Geometry and Cancellous Bone Architecture. J Bone Min Res 8:S259. 1993.
    133. Majumdar S, Weinstein RS, Prased RR, Genant HK. The Fractal Dimension of Trabecular Bone: A Measure of Trabecular Structure. Calcif Tissue Int 52:168. 1993.
    134. Mulloy AL, Mulloy LL, Weinstein RS. Hypercalcemia due to hard water used for home hemodialysis. South Med J. 1992; 85(11):1131 - 1133.
    135. Weinstein RS, Mulloy AL. Metabolic Bone Disease After Partial Gastrectomy. J Bone Min Res 7:S286. 1992.
    136. Weinstein RS. The Clinical Use of Bone Biopsy. 1992; 21.
    137. Mulloy AL, Mulloy LL, Weinstein RS. Hypercacemia Due to Hardwater Used During Dialysis. J Bone Min Res 7:S335. 1992.
    138. Weinstein RS, Majumdar S, Genant HK. Fractal Geometry Applied to the Architecture of Cancellous Bone Biopsy Specimens. Bone 13:A38. 1992.
    139. Weinstein RS. Elevated Ionized Calcium Concentration at the Onset of Hypocalcemic Symptoms After Neck Exploration for Severe Primary Hyperparathyroidism. J Bone Mineral Res 6:S302. 1991.
    140. Kent AB, Weinstein RS. Osteoclasts Cause Hypercalcemia in Acute Myelogenous Leukemia. Clin Res 39:838A. 1991.
    141. Weinstein RS, New KD, Sappington LJ. Dual-Energy Absorptiometry Measurements of the Radius. J Bone Mineral Res 6:S175. 1991.
    142. Weinstein RS. Anticonvulsant Drug-Induced Osteomalacia: Real or Imagined. ASBMR Workshop-Osteomalacia: Current Concepts and Controversy MK Drezner. 1990.
    143. Weinstein RS. Parathyroid Carcinoma and Polycythemia Vera. J Bone Mineral Res 5:S277. 1990.
    144. Cohen BE, Smith EM, Weinstein RS. Femoral, Lumbar and Radial Mineral Density is Increased in Black Compared to White Adults. Clin Res 38:32A. 1990.
    145. Weinstein RS. Parathyroid Carcinoma and Polycythemia Vera. Clin Res 38:990A. 1990.
    146. Sappington L, New K, Weinstein RS. Quantitative Digital Radiography (QDR) Versus Single Photon Absorptiometry (SPA) of the Radius. Clin Res 38:954A. 1990.
    147. Smith EM, Cohen BE, Weinstein RS. Asian-Indian and Oriental Americans Have Decreased Bone Density of the Hip Compared to Whites. Clin Res 38:33A. 1990.
    148. Weinstein RS. The cover photomicrograph and Chapter 48: Hypocalcemia in Acute Illness. 1990; 138-139.
    149. Smith EM, Cohen BE, Weinstein RS. Racial Differences in Bone Density. J Bone Mineral Res 5:S185. 1990.
    150. Weinstein RS. Osteomalacia. 1989; 193-194.
    151. Mulloy AL, Mulloy LL, Weinstein RS. Hard Water Induced Hypercalcemia During Home Dialysis. Clin Res 37:497A. 1989.
    152. Weinstein RS, Cheek PL. Redistribution of Skeletal Assets in Hemodialysis Patients. J Bone Mineral Res S1:169. 1989.
    153. Caruana RJ, Altman R, Fowler B, Blansit B, Chaudhary BA, Weinstein RS. Correlates of amylase and lipase levels in chronic dialysis patients. Int J Artif Organs. 1988; 11(6):454 - 458.
    154. Weinstein RS, Weinstein DL, Bell NH. Rates of Bone Formation and Mineral Apposition are Diminished in Normal Black Men and Women. J Bone Mineral Res 3S:89. 1988.
    155. Weinstein RS, Weinstein DL, Bell NH. Evidence for Diminished Rates of Mineralization and Bone Formation in Normal Blacks. Henry Ford Hosp Med J 36:148-9. 1988.
    156. Weinstein RS. Osteomalacia. 1988; 552-557.
    157. Weinstein RS, Hutson MS. Decreased Trabecular Width and Increased Trabecular Separation Contribute to Bone Loss With Aging. Clin Res 35:44A. 1987.
    158. Weinstein RS, Weinstein DL, Bell NH. Evidence for Diminished Rates of Mineralization and Bone Formation in Normal Black Men and Women. J Bone Mineral Res 2S:326. 1987.
    159. Weinstein RS, Gundberg CM. Multiple Immunoreactive Forms of Osteocalcin in the Sera of Dialysis Patients. J Bone Mineral Res 1:127. 1986.
    160. Weinstein RS. Osteoporosis. 1986; 480-483.
    161. Weinstein RS, Hutson MS. Decreased Trabecular Plate Thickness and Increased Trabecular Plate Spacing Contribute To Age-Related Loss of Bone. J Bone Mineral Res 1S:247. 1986.
    162. Roberts WE, Rosenoer LML, Weinstein RS. Nuclear Volume Analysis of Cells Lining Normal Human Trabecular Bone. J Bone Mineral Res 1S:123. 1986.
    163. Weinstein RS, Hutson MS. Both Increased Trabecular Plate Spacing and Decreased Trabecular Plate Thickness Contribute To Age-Related Bone Loss. Clin Res 34:199A. 1986.
    164. Rissing JP, Buxton TB, Weinstein RS, Shockley RK. Model of experimental chronic osteomyelitis in rats. Infect Immun. 1985; 47(3):581 - 586.
    165. Weinstein RS, Gundberg CM. Serum Osteocalcin is a Marker of Bone Remodeling in Dialysis Patients. Clin Res 32:853A. 1984.
    166. Weinstein RS. Rickets and Osteomalacia. In RE Rakel. 1984; 445-453.
    167. Weinstein RS, Gundberg CM. Serum Osteocalcin Levels Reflect Bone Mineralization. Calcif Tissue Int 36:499. 1984.
    168. Weinstein RS, Underwood JL, Hutson MS, DeLuca HF. Mineralization in Normocalcemic, Normophosphatemic Vitamin D-Deficient Rats. Clin Res 31:853A. 1983.
    169. Weinstein RS. Histological Heterogeneity of Osteoporosis. 1983.
    170. Weinstein RS, Gundberg CM. Serum Osteocalcin Levels Reflect Bone Mineralization in Osteopenic Patients. Clin Res 31:853A. 1983.
    171. Underwood J, Weinstein RS, DeLuca HF. Normal Bone Growth and Mineralization in D-deficient rats with normal plasma calcium and phosphorus. 1983.
    172. Weinstein RS. The Histological Heterogeneity of Osteopenia in the Middle-Aged and Elderly Patient. 1983; 211-225.
    173. Weinstein RS, Bryce CF, Gallagher BB. Decreased Serum Ionized Calcium and Normal Vitamin D Metabolite Levels with Anticonvulsant drugs. 1983.
    174. Caruana RJ, Weinstein RS. Hypercalcemia and nephrolithiasis provoked by serum phosphorus reduction in a patient with chronic renal failure and sarcoidosis. Nephron. 1983; 33(4):271 - 273.
    175. Weinstein RS. Focal mineralization defect during disodium etidronate treatment of calcinosis. Calcif Tissue Int. 1982; 34(3):224 - 228.
    176. Perry HM, Weinstein RS, Teitelbaum SL, Avioli LV, Fallon MD. Pseudofractures in the absence of osteomalacia. Skeletal Radiol. 1982; 8(1):17 - 19.
    177. Weinstein RS, Hutson MS. Histological Heterogeneity of Osteoporosis in the Middle-Aged and Elderly Patient. 1982; 375.
    178. Weinstein RS, Gallagher BB, Weinstein DL, Hutson MS, Sappington LJ, Murvin AJ. Decreased Serum Ionized Calcium Levels with Anticonvulsant Drugs. Clin Res 30:856A. 1982.
    179. Rissing JP, Weinstein RS, Buxton TB, Hutson MS. Experimental Staphylococcal Osteomyelitis in Rats: Histopathology and Therapeutic Efficacy of Oxacillin or Ceftriaxone. Clin Res 30:853A. 1982.
    180. Weinstein RS. Needle bone biopsy: how, when, why. Med Times. 1981; 109(5):2s - 13s.
    181. Weinstein RS, Sappington LJ. Qualitative Defect in Uremic Osteosclerosis. Clin Res 29:841A. 1981.
    182. Weinstein RS, Whyte MP. Heterogeneity of Adult Hypophosphatasia. 1981; 473.
    183. Weinstein RS. Increased osteoid in renal osteodystrophy after subtotal parathyroidectomy. 1981; 504.
    184. Weinstein RS, Simmons DJ, Lovejoy CO. Ancient Bone Disease in a Peruvian Mummy Revealed by Quantitative Skeletal Histomorphometry. Am J Phy Anthropol 54:321-326. 1981.
    185. Weinstein RS. Vitamin D Levels in the Hypercalcemia of Acute Renal Failure. Arch Intern Med 141:1101-1102. 1981.
    186. Weinstein RS, Hutson MS. Histological Heterogeneity of Osteoporosis in the Middle-Aged and Elderly Patient. Clin Res 29:841A. 1981.
    187. Weinstein RS, Sappington LJ. The Pathogenesis of Osteosclerosis. Calcif Tissue Int 33:312. 1981.
    188. Weinstein RS. Increase in Osteoid After Subtotal Parathyroidectomy in Hemodialysis Patients. 1981; 416.
    189. Weinstein RS, Ide LF. Immunoreactive calcitonin in pheochromocytomas. Proc Soc Exp Biol Med. 1980; 165(2):215 - 217.
    190. Weinstein RS. Occult Osteomalacia: A subset of Osteopenic Individuals. Calcif Tissue Int 31:67. 1980.
    191. Weinstein RS, Ide LF. Immunoreactive Calcitonin from Pheochromocytomas. 1980.
    192. Weinstein RS. Focal Mineralization Defect Resulting From Disodium Etidronate (EHDP). Clin Res 28:835A. 1980.
    193. Weinstein RS, Whyte MP. Heterogeneity of Adult Hypophosphatasia: Report of Mild and Severe Cases. Clin Res 28:835A. 1980.
    194. Weinstein RS, Carr AA. Osteomalacia in Pseudohypoparathyroidism. Clin Res 27:792A. 1979.
    195. Weinstein RS, Ide LF. Calcitonin in Pheochromocytoma. Clin Res 27:758A. 1979.
    196. Roof BS, Weinstein RS, Vujic I, Burdash NM. Heterogeneity of Calcitonin Determined by Differential Immunoreactivity and Column Chromatography in Medullary Carcinoma of Thyroid, Breast and Lung Cancer. Biomedicine 30:82-90. 1979.
    197. Weinstein RS. Needle Bone Biopsy: How, When, Why. Resident and Staff Physician 25:48-55. 1979.
    198. Weinstein RS, Bays RA. Rapid Loss of Alveolar Bone: A Clue to Metabolic Bone Disease. Clin Res 27:758A. 1979.
    199. Weinstein RS. Progressive Osteopenia of Twenty Years Duration: Eventual Diagnosis of Hypophosphatasia. 1979.
    200. Weinstein RS, Bransome ED. Osteogenesis Imperfecta Tarda: Histomorphometric Investigation of a Family. Clin Res 26:792A. 1978.
    201. Weinstein RS, Schwartzman R, Levey GS. Propranolol-Induced Reversal of Bulbar Dysfunction and Proximal Myopathy in a Patient with Hyperthyroidism. Ann Intern Med 82:540-541. 1975.
    202. Weinstein RS, Canterbury JM, Reiss E. Pseudohypoparathyroidism: Demonstration of abnormal metabolism of parathyroid hormone. Clin Res 22:569A. 1974.
    203. Adler RA, Saag K, Weinstein RS. Osteoporosis. Glucocorticoid-Induced Osteoporosis.
    204. Madhavaram P, Weinstein RS. Clinical Decision Support: Endocrinology. Osteomalacia.
    Weinstein's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (335) concept(s)
    _
    Co-Authors Expand Description
    See all (15) people
    _
    Similar People Expand Description
    See all (33) people
    _
    Same Department Expand Description
    Search Department